Drug Profile


Alternative Names: E-7080; ER-203492-00; Kisplyx; Lenvatinib mesylate; Lenvima

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; National University Hospital (Singapore); SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Preregistration Hepatocellular carcinoma
  • Phase II Biliary cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Thymoma
  • Phase I/II Breast cancer; Solid tumours
  • Phase I Cancer; Lymphoma; Ovarian cancer
  • Discontinued Glioma

Most Recent Events

  • 04 Oct 2017 Lenvatinib market licensed to Biotoscana in Latin America (excluding Mexico)
  • 26 Sep 2017 US FDA accepts sNDA for lenvatinib for Hepatocellular carcinoma for review
  • 11 Sep 2017 Eisai re-initiates a phase II trial in Thymoma (Metastatic disease, Late-stage disease, Recurrent) in Japan (PO) (UMIN000026777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top